CStone Pharmaceuticals (HKG:2616)

520.66% (1Y)

Market Cap	11.05B
Revenue (ttm)	433.34M
Net Income (ttm)	-97.06M
Shares Out	1.46B
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,576,087
Average Volume	18,137,633
Open	7.44
Previous Close	7.58
Day's Range	7.43 - 7.82
52-Week Range	1.17 - 7.70
Beta	0.15
RSI	83.65
Earnings Date	Aug 21, 2025

About CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 135
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2616

Financial Performance

In 2024, CStone Pharmaceuticals's revenue was 407.21 million, a decrease of -12.21% compared to the previous year's 463.84 million. Losses were -91.21 million, -75.16% less than in 2023.

Financial numbers in CNY